- Source type
- Government
- Access type
- Official
- Publisher
- U.S. Food and Drug Administration
- Date
- 2026-07-02
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
94
U.S. health regulator
- Publisher type
- Regulator
- Bias profile
- Low
This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 98/100
- Primary Anchor
- Clinical outcomes
- 84/100
- Strong Support
- Mechanism
- 68/100
- Context Source
- Safety
- 95/100
- Primary Anchor
- Consumer context
- 68/100
- Context Source
- Trial discovery
- 68/100
- Context Source
Best used for
- Approvals
- Labels
- Safety communications
Weak for
- Comparative effectiveness
- Consumer experience
Used in Viral Vitalism
FDA Flagged a Rare Genetic Anesthesia Safety Signal
Roles: Primary source
Related studies
No structured study record is currently attached to this source.
Related sources
FDA: Insulet removes certain Omnipod Pods
Primary Class I recall source for affected Omnipod Pods and insulin under-delivery risk.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
AABB: FDA warns against use of unapproved HCT/Ps
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- AABB
- Access
- Publisher
- Usage
- 1 connection
FDA Q&A: Proposed order for over-the-counter sunscreen
U.S. Food and Drug Administration used across the Viral Vitalism evidence library.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 9 connections
FDA: 2026 Safety and Availability Communications
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
FDA: Casgevy product page
Regulatory product-page context for Casgevy indication and safety boundaries.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection